Dr. Mark M. Tungesvik, MD
Hematology & Oncology (Hematology & Oncology Physician)
1705 E Broadway, Suite 100
Columbia, MO 65201
Who else practices at this address →
Boone County is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 926
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MO license 2005004970
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boone Hospital Center Columbia, MO
- Fitzgibbon Hospital Marshall, MO
Medical groups
- Missouri Cancer Associates LLC (22 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 926
- Services billed
- 194,394
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 47,330 | 52 |
| Injection, pembrolizumab, 1 mg | 32,200 | 45 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 25,550 | 14 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 20,551 | 188 |
| Injection, azacitidine, 1 mg | 15,500 | 12 |
| Injection, nivolumab, 1 mg | 14,980 | 14 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14,280 | 23 |
| Injection, ferric carboxymaltose, 1 mg | 14,250 | 17 |
| Injection, oxaliplatin, 0.5 mg | 13,800 | 21 |
| Injection, aprepitant, 1 mg | 13,520 | 49 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Columbia, MO | 228 |
| Hydroxyurea Other prescribers in Columbia, MO | 113 |
| Gabapentin Other prescribers in Columbia, MO | 111 |
| Fentanyl Other prescribers in Columbia, MO | 97 |
| Oxycodone Hcl Other prescribers in Columbia, MO | 95 |
| Prochlorperazine Maleate Other prescribers in Columbia, MO | 67 |
| Tamoxifen Citrate Other prescribers in Columbia, MO | 67 |
| Revlimid (lenalidomide) | 65 |
| Prednisone Other prescribers in Columbia, MO | 55 |
| Eliquis (apixaban) Other prescribers in Columbia, MO | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 138 payments worth $2,946 in total to this clinician.
| Food and Beverage | $2,442 |
|---|---|
| Education | $505 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Jun 27, 2025 | Education Enhertu · ONCOLOGY · in-kind | $99.99 |
| Sanofi-aventis U.S. LLC Nov 25, 2025 | Education SARCLISA · Oncology · in-kind | $99.95 |
| Seagen Inc. Sep 24, 2025 | Education in-kind | $99.95 |
| Lilly USA, LLC Feb 18, 2025 | Education in-kind | $90.79 |
| Gilead Sciences, Inc. Oct 28, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4203866;GTF;10026698 | $69.00 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $25.95 |
| Pfizer Inc. Mar 10, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $6.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.